Table 2.
Treatment response criteria.
| Time on therapy (months) | Treatment failure | Suboptimal response | Optimal response |
|---|---|---|---|
| 3* | No CHR | No CG response | CHR with <95% Ph+ |
| 6* | >95% Ph+ (no CyR) | 36–95% Ph+ (less partial CyR) | ≤35% Ph+ (partial CyR) |
| 12 | ≥35% Ph+ | 1–35% Ph+ (partial CyR) | 0% Ph+ |
| 18 | ≥1% Ph+ | <MMR | MMR |
| Any | Loss of CHR | Loss of MMR | Stable or improving MMR |
| Loss of CCyR | Imatinib-sensitive mutation | ||
| Mutation, CE |
European LeukemiaNet’s (ELN) criteria for patient failure and suboptimal response to imatinib therapy.
*
These criteria were modified in the 2013 update of the National Comprehensive Cancer Network guidelines.
CCyR, complete cytogenetic response; CE, clonal evolution; CG, cytogenetic; CHR, complete hematologic response; MMR, major molecular response; Ph, Philadelphia chromosome.